Open Nav

Interpace Diagnostics Group, Inc.

  • Jack Stover, Interpace Diagnostics

Educate the audience

  • Date:Thursday, October 18
  • Time:9:00 AM - 9:15 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT™, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates lung cancer of primary vs. metastatic origin.
  • Company Website:http://www.interpacediagnostics.com/
  • Company HQ City:Parsippany
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • Market Cap:$45M USD
  • Ticker:IDXG
  • Exchange:NASDAQ
  • CEO/Top Company Official:Jack Stover
  • Year Founded:April 2014 spin out from PDI Parent business
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development :ThyraMir/ ThyGeNEXT/ PancraGEN
  • Development Phase of Primary Product:Multiple Products in Market
Speakers
Jack Stover
Interpace Diagnostics
Back